Healthy Volunteers
Conditions
Brief summary
The purpose of this study is to evaluate the safety and tolerability of a single dose of HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses of HMPL-689 in healthy volunteers
Detailed description
Subjects will receive a single dose of HMPL-689 or matching placebo during Day 1. The planned dose levels are: 1, 2.5, 5, 10, 20, 25 and 30 mg (about 7 cohorts of 8 subjects). In each dose cohort, 8 subjects will be randomized to receive HMPL-689 (6 subjects) or placebo (2 subjects) under fed condition with a standard meal. For the first dose Cohort (1 mg), a sentinel group of 2 subjects (1 HMPL-689 and 1 placebo) will be dosed 24 hours prior to the planned dosing of the remaining six subjects. The decision of dose escalation or study termination will be made jointly by the principal investigator and the sponsor based on the clinical data (safety, tolerability, available PK data and clinical laboratory values). Any dose level may be repeated, reduced or split into 2 doses if deemed appropriate by the Principal Investigator and Sponsor's medical Expert.
Interventions
DRUGHMPL-689
selective PI3Kδ inhibitor
DRUGHMPL-689 placebo
placebo of HMPL-689
Sponsors
Hutchison Medipharma Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Informed consent must be obtained in writing for all subjects before enrollment into the study 2. Healthy male subjects aged 18 to 45 years inclusive at the time of screening 3. Body mass index ≥19.0 and ≤ 30.0 kg/m2 4. Willing to comply with the contraceptive requirements of the study and must not donate sperm during the study or for 3 months afterwards. Subjects must agree to use a condom or to abstain from sexual intercourse throughout the trial and for 30 days afterwards
Exclusion criteria
1. Family history of premature Coronary Heart Disease 2. History of immunosuppression or opportunistic infections or receipt of a live virus vaccination within the 3 months prior to screening 3. Clinically significant abnormalities as determined by medical history physical examination, or laboratory test, especially for liver and renal function 4. Clinically significant findings in ECG, blood pressure and heart rate, as determined by the Clinical Investigator 5. Subjects at risk for tuberculosis (TB), which is defined as: 1. Current clinical or laboratory evidence of active TB 2. History of TB 3. A positive QuantiFERON® test at screening or within 6 months prior to Day 1 6. Any medical condition requiring regular use of medication 7. Exposure to prescription medications within 30 days prior to Day 1 8. Exposure to any other medication, including over-the-counter medications, herbal remedies and vitamins 14 days prior to first dose (except for paracetamol) 9. Participation in another clinical trial with any investigational drug within 30 days of Day 1 10. Treatment in the previous 3 months with any drug known to have a well-defined potential for toxicity to a major organ 11. Current smoker of more than 10 cigarettes or equivalent/ day prior to commencing the study and unable to completely stop smoking during the study 12. Symptoms of a clinically significant illness in the 3 months before the study 13. Presence or sequelae of gastrointestinal, liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs 14. Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease, hemorrhoids or anal diseases with regular or recent presence of blood in feces 15. History of significant allergic disease (e.g. allergic to medications) and acute phase of allergic rhinitis in the previous 2 weeks before randomization/ enrollment or any food allergy 16. Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, or current known active infection with HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) 17. Current evidence of drug abuse or history of drug abuse within one year before randomization/ enrollment 18. Mental condition rendering the subject incapable to understand the nature, scope, and possible consequences of the study 19. Unlikely to comply with the clinical study protocol; e.g. uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study 20. Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| dose limited toxicities evaluated with NCI CTCAE v4.03 | within 28 days after the first dose | Incidence of dose limited toxicities and associated dose of HMPL-689 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| maximum plasma concentration calculated with Blood samples | within 29 days after the first dose | Blood samples will be taken to measure the levels of study drug |
| time to reach maximum concentration calculated with Blood samples | within 29 days after the first dose | Blood samples will be taken to measure the levels of study drug |
Countries
Australia
Outcome results
None listed